11月6日，苏州旺山旺水生物医药股份有限公司（以下简称“旺山旺水”，股票代码：2630.HK）在香港联交所主板挂牌上市，光大证券国际担任该项目的联席账簿管理人。本次IPO全球发售17,597,800股H股，每股定价33.37港元，香港公开发售股份获认购约6,238倍，上市共募集款项净额约5.27亿港元。旺山旺水是一家成立于2013年的生物医药公司，从事发现、获取、开发和商业化创新小分子药物，聚焦...
Source Link11月6日，苏州旺山旺水生物医药股份有限公司（以下简称“旺山旺水”，股票代码：2630.HK）在香港联交所主板挂牌上市，光大证券国际担任该项目的联席账簿管理人。本次IPO全球发售17,597,800股H股，每股定价33.37港元，香港公开发售股份获认购约6,238倍，上市共募集款项净额约5.27亿港元。旺山旺水是一家成立于2013年的生物医药公司，从事发现、获取、开发和商业化创新小分子药物，聚焦...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.